Corporate | 12 August 2016 07:00
Carl Zeiss Meditec AG: Carl Zeiss Meditec AG grows in Ophthalmology and Microsurgery
|
DGAP-News: Carl Zeiss Meditec AG / Key word(s): 9-month figures
Press Release Carl Zeiss Meditec AG grows in Ophthalmology and Microsurgery Revenue, EBIT and earnings per share show positive development JENA, 12 August 2016 In the first nine months of fiscal year 2015/16 medical technology company Carl Zeiss Meditec AG increased its revenue by 6.7 percent to EUR 798.6 million (adjusted for currency effects: 4.5 percent). All Strategic Business Units (SBU) and regions contributed to growth in the reporting period, however, at varying rates. Earnings before interest and taxes (EBIT) at EUR 110.5 million (prior year: EUR 89.5 million) developed positively, corresponding to an EBIT margin at 13.8 percent (prior year: 12.0 percent). Earnings per share were EUR 0.83 (prior year EUR 0.64). Substantial growth was posted by the two strategic business units of Ophthalmology: The Ophthalmic Systems SBU (OPH) increased revenue after nine months by 7.5 percent to EUR 304.9 million compared to EUR 283.5 million in the same period of the previous year. Adjusted for currency effects, revenue increased by 5.0 percent. The Surgical Ophthalmology SBU (SUR) increased its revenue by 8.6 percent (adjusted for currency effects: 7.1 percent) to EUR 280.8 million (prior year: EUR 258.5 million). In the Microsurgery SBU, revenue growth was 3.0 percent and mainly due to favorable exchange rates. Revenue climbed to EUR 212.8 million, compared with EUR 206.7 million in the same period of the previous year. Based on constant exchange rates, growth would have been 0.6 percent. Asia once again growth engine In the reporting regions, the major part of growth was accounted for by the APAC region in the first three quarters of the current fiscal year. In the EMEA region, a slight increase in revenue was reported by 0.2 percent to EUR 262.5 million (prior year: EUR 261.9 million), whereas Germany and France enjoyed growth. However, the business trend in Middle East and Africa was declining.
Revenue in the Americas region increased by 0.9 percent to EUR 257.3 million (prior year: EUR 255.2 million). The strength of the US dollar had a positive effect in this region.
The APAC region generated revenue of EUR 278.7 million which is significantly higher than the year-ago figure of EUR 231.6 million – an increase by 20.3 percent. Adjusted for slight currency effects, growth would still have been 17.1 percent. The lion’s share of the increase came from the Chinese market as well as from Southeast Asia and South Korea; the Japanese market exhibited a sideways trend. Dr. Ludwin Monz, CEO of Carl Zeiss Meditec AG, believes the Company is on the right track and – in view of the 9-month figures – confirmed the forecast for the current fiscal year with an annual revenue in the range of EUR 1,080 – 1,120 million. “The result of the first three quarters endorses our growth strategy. In particular the innovations launched recently supported us to expand our market position, especially in Asia.” In view of the recently announced consolidation to focus the organizational structure on the two core markets of the company, microsurgery and ophthalmology, he said: “We want to improve service for our customers and tap into potentials in various regional markets.” Revenue by strategic business unit
Revenue by region
Press contact:
Investors contact:
Brief profile
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The company supplies innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditec AG’s medical technology portfolio is rounded off by promising future technologies such as intra-operative radiotherapy. With around 2,900 employees, the Group generated revenue of EUR 1,040 million in fiscal year 2014/15 (30 September
The head office of the Carl Zeiss Meditec Group is in Jena, Germany. The Company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application & Research India (CARIn) in Bangalore, India and the ZEISS Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around
For more information visit our website at: www.zeiss.de/med
2016-08-12 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
|
| Language: | English | |
| Company: | Carl Zeiss Meditec AG | |
| Göschwitzer Str. 51-52 | ||
| 07745 Jena | ||
| Germany | ||
| Phone: | +49 (0)3641 220-0 | |
| Fax: | +49 (0)3641 220-112 | |
| E-mail: | investors.meditec@zeiss.com,info.meditec@zeiss.com | |
| Internet: | www.meditec.zeiss.de | |
| ISIN: | DE0005313704 | |
| WKN: | 531370 | |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange | |
| End of News | DGAP News Service |